Market Overview
The
Global Cell Therapy Market size is expected to reach a value of
USD 7.0 billion in 2024, and it is further anticipated to reach a value of
USD 32.5 billion by 2033 at a CAGR of 18.6%.
This marketplace is focused on the research, development, and production of cell-based treatment plans used for the treatment of numerous conditions, consisting of most cancers, cardiovascular ailments, musculoskeletal disorders, autoimmune issues, and rare medical conditions. Cell therapy, a form of regenerative medicinal drug, utilizes live human blood cells (inclusive of stem cells, lymphocytes, and dendritic cells) to deal with continual, acute, and uncommon
medical conditions. The marketplace gives diverse cellular products inclusive of stem cell therapies, CAR-T cell therapy procedures, and tissue-engineered products, tailored to specific medical conditions. Ongoing research and technological advancements are expanding the capabilities and applications within this quarter, extensively driving the market growth.
This marketplace may be prompted by way of various factors that impact the development, commercialization, and adoption of cell-based therapies in the
healthcare sector. The ongoing research and technological development in cell therapy, in addition to the improvement of the latest therapies, drive the growth of this market. The increase of research institutions, hospitals, and the healthcare sector ultimately impacts the growth of the global cell therapy market, as they're moving the point of interest of studies on producing more secure, more powerful, and innovative scientific treatment which will push the boundaries of treatment plans for many rare diseases.
Regulatory bodies just as the CDC, WHO, and FDA within the United States and their counterparts all around the globe play an important role in shaping this marketplace. They approve and assess the drug treatments and cures earlier than they're released in the marketplace. The outcomes of the clinical trials and research appreciably affect the cell therapy market. The fine consequences of these trials can revolutionize this market, whereas negative results can hinder years’ worth of research and growth. These approvals and regulations in the cell therapy market impact the growth of the global cell therapy market.
The growth of the cell therapy market is expected to drive growth significantly over the forecast period. According to a comprehensive cell therapy market analysis, the cell therapy market is segmented by therapy type and therapeutic area. Key players in the market, such as Tameika Cell Technologies and Stemedica Cell Technologies, are actively operating in the cell therapy space. Allogeneic cell therapies and new cell manufacturing innovations are among the factors expected to drive growth. The cell and gene therapy manufacturing process is crucial for successful cell therapy production, impacting market insights and cell therapy market share. Institutes for stem cell biology, such as the Institute for Stem Cell Biology and Regenerative Medicine, contribute to advancing stem cell biology and regenerative medicine. Companies operating in the cell therapy industry rely on efficient cell manufacturing processes to meet the increasing demand.
Cell therapy clinical studies provide valuable data that inform market insights and strategies. The report's scope covers various aspects of cell biology, cell therapy research, and therapy production. The human cell foundry and other companies in the market are investing in gene and cell therapy to maintain their competitive edge. Players in the cell therapy market, including Cell Technologies Inc., have dominated the cell therapy market by leveraging their expertise in cell and gene therapy manufacturing.
Key Takeaways
- Market Size: The cell therapy market size is expected to grow substantially, with a forecasted value of USD 32.5 billion by 2033.
- Therapy Dominance: Autologous therapies hold a dominant market share, driven by their personalized approach and compatibility with patients' immune systems.
- Therapeutic Focus: Oncology remains a primary focus area, accounting for a significant market share due to the high demand for innovative cancer treatments.
- Regional Dominance: North America leads the market, supported by advanced healthcare infrastructure and strong regulatory frameworks.
- Competitive Landscape: The market is highly competitive, with major pharmaceutical and biotechnology firms heavily investing in research and development.
Use Cases
- Cancer Treatment: Innovative cell therapies like CAR-T cell therapy have shown high success rates in treating hematologic malignancies such as leukemia and lymphoma.
- Cardiovascular Disease: Cell therapies are being developed to repair and regenerate heart tissue, offering new treatment options for patients with cardiovascular diseases.
- Autoimmune Disorders: Personalized cell therapies are providing new avenues for treating autoimmune disorders with higher success rates and fewer side effects.
- Musculoskeletal Disorders: Cell-based treatments, including mesenchymal stem cell therapy, offer regenerative solutions for musculoskeletal conditions like osteoarthritis and spinal cord injuries, promoting tissue repair and functional improvement in affected patients.
Market Dynamic
Trends
Increased Adoption of Autologous TherapiesThe global cell culture market is witnessing an increasing trend of autologous therapies, which refers to treatments derived from the patient’s cells. This trend stems from the need for individualization of medication. It increases compatibility and minimizes the chances of various side effects; all these aspects affect overall market progression.
Advancements in Stem Cell Research
Technological advancements and research in stem cell treatments are playing a major role in determining the market factors. These innovations are improving the prospects of treatment of different diseases such as cancer and cardiovascular disease for the cell therapy business and are steadily increasing the cell therapy market size.
Growth Drivers
Technological Advancements
The integration of cutting-edge technologies in cell therapy procedures and rising emphasis on the application of information technologies in the cell therapy processes is another factor that defines market growth. These innovations are enhancing the possibilities of cell therapies and therefore improving the efficiency of treatments and minimizing risks hence a positive implication on the market outlook.
Government Support and Funding
Favorable government policies to support funding and regulation are enhancing the capabilities of research institutes to advance cell therapies. This support is largely beneficial for the growth of the global cell therapy market, it has led to constant improvement and approval of new therapies.
Growth Opportunities
Emerging Markets in Asia-Pacific
The Asia-Pacific region is particularly beneficial for development since a majority of investors have invested in healthcare infrastructure and research centers. The market growth in this region is expected to be fueled by the anticipated growth of its markets, which is anticipated to open more opportunities for growth in the worldwide market.
Development of Non-Stem Cell Therapies
The continued therapeutic research and highly growing opportunities in Stem Cell therapies help note its promising growth opportunities. These therapies such as T-cell and dendritic cell therapies are helping the growth of the market by covering more areas of treatments for various diseases and conditions.
Restraints
High Cost of Cell Therapy Treatments
In the existing market, one of the most cogent inhibitors of cell therapy has to do with the soaring expenses incurred during the treatment. This is a cost factor that makes the therapies expensive and thus not easily accessible to many patients, thereby slowing down the market growth rate.
Regulatory Challenges
Reimbursements and regulatory concerns as well as time-consuming regulatory processes are factors that hinder the advancement of cell therapies for commercialization. Some of these regulatory barriers can prolong the time it takes for new therapies to get to the market, which in turn influences cell therapy market size and its compound growth rate.
Research Scope and Analysis
By Therapy Type
In terms of the type of therapy that is used in the treatment of patients, Autologous therapy is projected to dominate this market as it is forecasted to hold 93.1% of the market share in 2024. Autologous treatment dominates this market as it entails the usage of patient's own blood cells for their treatment. This personalized and specially designed treatment therapy to deal with specific medical situations in line with patients’ requirements is commonly safer because of the compatibility of the cells to the patient's immune system, as it reduces the likelihood of unfavorable reactions and minimizes the risk of graft versus host disorder or rejection that is generally associated with allogeneic therapies.
Additionally, those therapies can be customized according to the specific needs of every patient, making them ideal for medical conditions that require personalized treatment like most cancers and autoimmune diseases. Autologous cell therapies hold a primary part of this marketplace due to the data it can be applied to an extensive variety of medical conditions from dermatology to the treatment of autoimmune disorders. In other words, autologous cell treatment dominates the global cell therapy marketplace because it's far preferred by healthcare professionals for its better success rate, compatibility with patients, and broad clinical applicability.
By Therapeutic Area
Based on the therapeutic area, Oncology, a branch of medicine dedicated to the study and treatment of cancer, is expected to dominate this segment as it holds 39.2% of the market share in 2024 and is projected to show significant growth in this market in the forthcoming years as well.
Cancer is the main reason for morbidity and high mortality rates globally. That's why the need for an effective and innovative treatment for this disorder is critical. The excessive range of cancer instances around the sector drives the sizable growth for its revolutionary and effective treatment. Cell therapy holds exceptional potential in concentrating on and treating numerous varieties of cancer instances. In the case of cancer, cellular therapy gives innovative and personalized treatment plans in step with patients' clinical condition.
Cellular treatments like CAR-T cellular therapy have proven an exceptional achievement rate in treating hematologic malignancies like leukemia and lymphoma. Oncology remains the number one attention for research and development in the medical field and it is also endorsed through both government and private organizations as they offer investment and resources for further research. Despite large progress in oncology, there are nevertheless cases when patients with aggressive forms of cancer cannot be saved. In such instances, cell treatment offers new hope to patients who may not reply to conventional therapies. So, the capability to provide powerful, targeted, and potentially curative treatment for various cancer types has positioned oncology at the leading edge of the cell therapy market.
The Cell Therapy Market Report is segmented on the basis of the following
By Therapy type
- Autologous Therapies
- Stem Cell Therapies
- BM, Blood & Umbilical Cord-derived Stem Cells
- Adipose-derived cells
- Others
- Non-Stem Cell Therapies
- Allogenic Therapies
- Stem Cell Therapies
- Hematopoietic Stem Cell Therapies
- Mesenchymal Stem Cell Therapies
- Non-Stem Cell Therapies
- Keratinocytes & Fibroblast-based Therapies
- Others
By Therapeutic Area
- Oncology
- Cardiovascular Disease (CVD)
- Musculoskeletal Disorders
- Dermatology
- Others
Regional Analysis
North America is projected to assert its dominance in the global cell therapy market, as it
holds 67.1% of the market share in 2024 and is expected to show significant growth in the upcoming period of 2033. This region has been dominating the market due to its maturity through the availability of an enhanced environment that enhances the growth of the healthcare industry to support the development of cell therapies.
Also, several reputed universities for research are located in this region, such as Johan Hopkins University, the Harvard University among others which are at the forefront of the research on cell therapies and which assist in enhancing medical breakthroughs. Typically, governmental agencies such as the US Food and Drug Administration, and FDA, have set the proper direction for the development and authorization of cell therapy types of treatment.
These regulatory measures given by the government give a sense of security to the companies and investors so that they can invest in this region. All these factors benchmark this region as one of the strategic front runners in the development of the global cell therapy market. North America has the most sophisticated system of healthcare, well-developed research bases, support at the legislative level, and the pioneer’s position in the development of cell therapy.
By Region
North America
Europe
- Germany
- The U.K.
- France
- Italy
- Russia
- Spain
- Benelux
- Nordic
- Rest of Europe
Asia-Pacific
- China
- Japan
- South Korea
- India
- ANZ
- ASEAN
- Rest of Asia-Pacific
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of Latin America
Middle East & Africa
- Saudi Arabia
- UAE
- South Africa
- Israel
- Egypt
- Rest of MEA
Competitive Landscape
The competitors’ analysis of the cell therapy market revealed that the market has high levels of competitiveness on the part of the key players who are targeting market share and differentiation strategies over their rivals. Addressing this market involves the identification and engagement of pharmaceutical firms, biotechnology companies, academic research institutions as well as other innovative firms, including startups. Some of the dominating players in this market are Novartis, Gilead Sciences, Johanson & Johnson which already have a deep research in innovation and introduction of a new product line in the cell therapy market. Further, instances, where key institutions such as Harvard University, University of California, and Berkeley have been involved in elaborate research work in a bid to expand the cell therapy market, have also occurred many times.
It is easy to come across many practices of research transforming into clinical operations and the commercial realm. In line with this, huge pharma firms tend to outsource from smaller-sized biotechnology companies that offer the chance to possess advanced technologies in cell therapy. Companies primarily involved in this sector are Novartis AG, Gilead Sciences Inc., Bristol-Myers Squibb Company, Johnson & Johnson Services Inc., JCR Pharmaceutical Company Limited, Bluebird Bio Inc., Dendreon Corporation, and others.
Some of the prominent players in the Global Cell Therapy Market are
- Novartis AG
- Gilead Sciences Inc.
- Bristol-Myers Squibb Company
- Johnson & Johnson Services Inc.
- JCR Pharmaceutical Company Limited
- Tego Science
- Atara Biotherapeutics
- Takeda Pharmaceutical Company Limited
- Bluebird Bio Inc.
- Dendreon Corporation
- Other Key Players
Recent Developments
April 2023: Bristol Myers Squibb and Novartis enhanced cell therapy capabilities by introducing a U.S. manufacturing facility for viral vector production of CAR T cell therapies, boosting production efficiency and capacity.
March 2023:
- Danaher partnered with the University of Pennsylvania to tackle manufacturing challenges affecting cell therapy adoption, aiming to streamline production processes and enhance the accessibility of cell-based treatments.
- Arsenal Biosciences, Inc. and Thermo Fisher Scientific collaborated to improve manufacturing processes for new cancer treatments, developing a robust process for next-generation, programmable autologous T cells for enhanced cancer therapy efficacy.
December 2022:
- Kite, a Gilead Company, acquired Tmunity Therapeutics to develop advanced CAR T-cell therapies, gaining access to pre-clinical and clinical projects and an 'armored' CAR T technology platform to boost anti-tumor efficacy.
- Kite and Arcellx, Inc. formed a strategic alliance to develop and commercialize CART-ddBCMA for treating relapsed multiple myeloma, aiming to improve treatment options and outcomes for affected patients.
June 2022: BlueRock Therapeutics completed enrollment in its Phase 1 study evaluating the safety and preliminary efficacy of its investigational cell-based therapy BRT-DA01 for advanced Parkinson’s disease, targeting motor symptoms.
March 2022:
- Novartis received FDA approval for Kymriah® CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma, expanding the therapy's indications and providing a new treatment option for this patient group.
- Miracell, a Korean stem cell therapy company, announced its entry into the Middle East market after successful ventures in Europe, aiming to expand its global reach and market presence.
February 2022: Thermo Fisher Scientific launched comprehensive commercial packaging and distribution services to support patients transitioning from clinic to commercial release across the U.S. and Europe, enhancing logistics strategies.
January 2022:
Immunocore received FDA approval for KIMMTRAK (tebentafusp-tebn) for treating unresectable or metastatic uveal melanoma, providing a new therapeutic option for patients with this challenging condition.
Report Details
| Report Characteristics |
| Market Size (2024) |
USD 7.0 Bn |
| Forecast Value (2033) |
USD 32.5 Bn |
| CAGR (2024-2033) |
18.6% |
| Historical Data |
2018 – 2023 |
| Forecast Data |
2024 – 2033 |
| Base Year |
2023 |
| Estimate Year |
2024 |
| Report Coverage |
Market Revenue Estimation, Market Dynamics, Competitive Landscape, Growth Factors and etc. |
| Segments Covered |
By Therapy Type (Autologous Therapies and Allogenic Therapies), By Therapeutic Area (Oncology, Cardiovascular Disease (CVD), Musculoskeletal Disorders, Dermatology and Others) |
| Regional Coverage |
North America – The US and Canada; Europe – Germany, The UK, France, Russia, Spain, Italy, Benelux, Nordic, & Rest of Europe; Asia- Pacific– China, Japan, South Korea, India, ANZ, ASEAN, Rest of APAC; Latin America – Brazil, Mexico, Argentina, Colombia, Rest of Latin America; Middle East & Africa – Saudi Arabia, UAE, South Africa, Turkey, Egypt, Israel, & Rest of MEA
|
| Prominent Players |
Novartis AG, Gilead Sciences Inc., Bristol-Myers Squibb Company, Johnson & Johnson Services Inc., JCR Pharmaceutical Company Limited, Tego Science, Atara Biotherapeutics, Takeda Pharmaceutical Company Limited, Bluebird Bio Inc., Dendreon Corporation and Other Key Players. |
| Purchase Options |
We have three licenses to opt for: Single User License (Limited to 1 user), Multi-User License (Up to 5 Users), and Corporate Use License (Unlimited User) along with free report customization equivalent to 0 analyst working days, 3 analysts working days and 5 analysts working days respectively. |
Frequently Asked Questions
The Global Cell Therapy Market is expected to reach a value of USD 7.0 billion in 2024.
The Global Cell Therapy Market is primarily focused on the research & development and production of cell-based therapies that are primarily used in the treatment of cancer, cardiovascular disease, musculoskeletal disorders, and rare health conditions.
The key players in this market are Novartis AG, Gilead Sciences Inc., Bristol-Myers Squibb Company, Johnson & Johnson Services Inc., JCR Pharmaceutical Company Limited, Bluebird Bio Inc., Dendreon Corporation, and others.
North America, asserts its dominance in the global cell therapy market, as it holds 67.1% of the market share in 2024 and is expected to hold subsequent growth in the upcoming period of 2033.